Forum Financial Management LP Boosts Stake in Johnson & Johnson (NYSE:JNJ)

Forum Financial Management LP raised its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 31.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 32,409 shares of the company's stock after purchasing an additional 7,826 shares during the period. Forum Financial Management LP's holdings in Johnson & Johnson were worth $4,687,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Sulzberger Capital Advisors Inc. purchased a new position in Johnson & Johnson in the 4th quarter worth $453,000. Oregon Pacific Wealth Management LLC purchased a new position in shares of Johnson & Johnson in the fourth quarter valued at about $949,000. Horan Securities Inc. increased its position in shares of Johnson & Johnson by 1.3% in the fourth quarter. Horan Securities Inc. now owns 7,178 shares of the company's stock valued at $1,038,000 after acquiring an additional 90 shares during the period. Strategic Financial Concepts LLC increased its position in shares of Johnson & Johnson by 57.9% in the fourth quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company's stock valued at $501,000 after acquiring an additional 1,271 shares during the period. Finally, State of Wyoming increased its position in shares of Johnson & Johnson by 205,580.0% in the fourth quarter. State of Wyoming now owns 10,284 shares of the company's stock valued at $1,487,000 after acquiring an additional 10,279 shares during the period. 69.55% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on JNJ shares. Sanford C. Bernstein reiterated a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Barclays reduced their price target on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 17th. Guggenheim reiterated a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Leerink Partners cut shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and reduced their price target for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Finally, Raymond James cut their price objective on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a report on Monday, April 14th. Eleven research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus target price of $170.88.

Johnson & Johnson Stock Performance

Johnson & Johnson stock traded up $0.31 during midday trading on Tuesday, reaching $153.25. 6,979,759 shares of the company traded hands, compared to its average volume of 9,392,354. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The firm has a market capitalization of $368.73 billion, a price-to-earnings ratio of 23.05, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42. The business has a 50 day moving average of $155.05 and a two-hundred day moving average of $153.65.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. As a group, research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 3.39%. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date is Tuesday, May 27th. Johnson & Johnson's dividend payout ratio is presently 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.